美股異動 | 美國生物製藥廠吉利德科學盤前漲2% 二季度業績勝預期 調高全年預測
格隆匯8月3日丨吉利德科學(GILD.US)盤前漲2%,報60.73美元。吉利德科學公佈,截至6月底止第二季,利潤降至11.4億美元,去年同期獲利15.2億美元;每股經調整盈利為1.58美元,優於市場預期的1.52美元;收入升1%至63億美元,優於市場預期的58.5億美元。集團表示,新冠治療藥物瑞德西韋(remdesivir)第二季收入跌45%至4.45億美元,優於市場預期的3.9億美元。吉利德輕微上調年度每股盈利預測,由6.2至6.7美元修訂為6.35至6.75美元;收入預料介乎245億至250億美元,原先為238億至243億美元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.